FDA WARNING_LETTER - XLPharmacy

The FDA issued a Warning Letter to XLPharmacy for offering unapproved and misbranded opioid products, specifically "Tramadol Generic (Ultrum)," for sale to U.S. consumers, violating the Federal Food, Drug, and Cosmetic Act (FD&C Act).

The products are deemed "new drugs" under section 201(p) of the FD&C Act because they lack FDA approval for safety and effectiveness, violating sections 301(d) and 505(a). The letter highlights that while FDA-approved tramadol exists, XLPharmacy's "Ultrum" version is unapproved and lacks the required boxed warning for risks like addiction, respiratory depression, and neonatal opioid withdrawal syndrome.

Furthermore, the products are "misbranded" under section 502(f)(1) because they lack adequate directions for safe use by a layperson. As prescription drugs, they require supervision by a licensed practitioner, and adequate directions cannot be provided for self-treatment, violating section 301(a).

The FDA emphasizes the inherent risks of unapproved drugs, including potential contamination, counterfeiting, and inconsistent active ingredients, especially amid the opioid epidemic. XLPharmacy is required to immediately cease offering violative drugs and respond in writing within 10 working days, detailing corrective actions and a timeline to prevent recurrence. Failure to comply may result in regulatory actions like seizure or injunction. The letter also lists associated websites in XLPharmacy's